Francesco Graziano

Summary

Country: Italy

Publications

  1. pmc Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    BMC Cancer 1:9. 2001
  2. ncbi request reprint A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 11:1263-6. 2000
  3. ncbi request reprint Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Tumour Biol 25:106-10. 2004
  4. doi request reprint Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy
    Francesco Graziano
    Department of Onco Hematology, Division of Oncology, Azienda Ospedale San Salvatore, Pesaro, Italy
    Pharmacogenomics 11:1247-56. 2010
  5. ncbi request reprint Association of thymidylate synthase polymorphisms with gastric cancer susceptibility
    Francesco Graziano
    Medical Oncology, Hospital of Urbino, Italy
    Int J Cancer 112:1010-4. 2004
  6. ncbi request reprint Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Via Bonconte da Montefeltro, 61029, Urbino, Italy
    J Clin Oncol 23:2339-45. 2005
  7. ncbi request reprint Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population
    Francesco Graziano
    Department of Medical Oncology, Hospital of Urbino, Urbino, Italy
    Int J Cancer 118:628-32. 2006
  8. doi request reprint Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
    F Graziano
    Department of Onco Hematology, Medical Oncology Unit, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Pharmacogenomics J 10:458-64. 2010
  9. doi request reprint Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
    F Graziano
    Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy
    Pharmacogenomics J 9:78-84. 2009
  10. pmc Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
    F Graziano
    Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Br J Cancer 99:716-21. 2008

Detail Information

Publications40

  1. pmc Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    BMC Cancer 1:9. 2001
    ..According to this hypothesis, we investigated the p53 and the DCC proteins expression in different stages of gastric carcinomas...
  2. ncbi request reprint A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 11:1263-6. 2000
    ..In this study, we explored the activity of weekly docetaxel in patients with advanced gastric cancer who failed first-line chemotherapy...
  3. ncbi request reprint Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Tumour Biol 25:106-10. 2004
    ..Some of the mechanisms inducing E-cadherin downregulation, like hypermethylation, may be potentially reversible, and they deserve further investigation as the target of novel therapeutic strategies...
  4. doi request reprint Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy
    Francesco Graziano
    Department of Onco Hematology, Division of Oncology, Azienda Ospedale San Salvatore, Pesaro, Italy
    Pharmacogenomics 11:1247-56. 2010
    ..We investigated whether IGFBP-3 SNPs determining high IGFBP-3 circulating levels are associated with improved survival of patients with advanced gastric cancer treated with palliative chemotherapy...
  5. ncbi request reprint Association of thymidylate synthase polymorphisms with gastric cancer susceptibility
    Francesco Graziano
    Medical Oncology, Hospital of Urbino, Italy
    Int J Cancer 112:1010-4. 2004
    ..In vitro, 3G genotypes have been related to high TS mRNA expression, which may underlie one of the possible etiologic mechanisms...
  6. ncbi request reprint Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Via Bonconte da Montefeltro, 61029, Urbino, Italy
    J Clin Oncol 23:2339-45. 2005
    ..The prognostic role of IL-1B/IL-1RN genotypes was investigated in patients with relapsed and metastatic gastric cancer treated with palliative chemotherapy...
  7. ncbi request reprint Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population
    Francesco Graziano
    Department of Medical Oncology, Hospital of Urbino, Urbino, Italy
    Int J Cancer 118:628-32. 2006
    ..Possession of the MTHFR677T/T genotype was significantly associated with genomic DNA hypomethylation. These findings deserve further investigation in the context of novel strategies for gastric cancer prevention...
  8. doi request reprint Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
    F Graziano
    Department of Onco Hematology, Medical Oncology Unit, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Pharmacogenomics J 10:458-64. 2010
    ..These findings deserve additional investigations as they may open novel perspectives for the treatment of patients with MCRC...
  9. doi request reprint Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer
    F Graziano
    Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy
    Pharmacogenomics J 9:78-84. 2009
    ..002). These findings encourage additional studies in this field and the evaluation of a recombinant-IL-1RA for anticancer activity...
  10. pmc Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
    F Graziano
    Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Br J Cancer 99:716-21. 2008
    ..Liver-only MCRC patients are a homogeneous and clinical relevant subgroup that may represent an ideal setting for studying the actual influence of TS polymorphisms...
  11. doi request reprint Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy
    J Clin Oncol 26:1427-34. 2008
    ..We investigated possible associations between genetic variants and clinical outcomes of MCRC patients treated with cetuximab-irinotecan salvage therapy...
  12. ncbi request reprint Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Clin Cancer Res 10:2784-9. 2004
    ..In this perspective, we investigated whether hypermethylation in the CDH1 promoter region is correlated with poor prognosis of patients with surgically resected, node-positive, diffuse gastric cancer...
  13. pmc Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Via Bonconte da Montefeltro, 61029 Urbino, Italy
    Br J Cancer 86:1854-7. 2002
    ..In selected patients, levocarnitine supplementation may be effective in alleviating chemotherapy-induced fatigue. This compound deserves further investigations in a randomised, placebo-controlled study...
  14. ncbi request reprint Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    Ann Oncol 14:1026-38. 2003
    ..Markers of altered DCC function have shown promising prognostic role and sufficient prevalence in retrospective investigations and they deserve further assessment in prospective studies...
  15. ncbi request reprint Screening E-cadherin germline mutations in Italian patients with familial diffuse gastric cancer: an analysis in the District of Urbino, Region Marche, Central Italy
    Francesco Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Tumori 89:255-8. 2003
    ..In this area, we investigated CDH1 mutations in patients who fulfilled the hereditary diffuse gastric cancer criteria...
  16. pmc A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Br J Cancer 89:1428-32. 2003
    ..The weekly PLF regimen resulted safe and effective in elderly patients with advanced GC. This outpatient regimen is based on old and low-cost drugs and it may represent an alternative to new and more expensive combinations...
  17. doi request reprint Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer
    Francesco Graziano
    Azienda Ospedaliera Ospedali Riuniti Marche Nord 61122, Pesaro, Italy
    J Clin Oncol 29:4789-95. 2011
    ..To investigate whether prognosis of patients with high-risk gastric cancer may depend on MET copy number gain (CNG) or an activating truncation within a deoxyadenosine tract element (DATE) in the promoter region of the MET ligand HGF...
  18. ncbi request reprint The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 14:1705-13. 2003
    ..CDH1 promoter hypermethylation seems a key event in the carcinogenetic process of poorly differentiated, diffuse gastric cancer and it deserves further investigation as a new target for anticancer therapies with demethylating agents...
  19. ncbi request reprint Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs
    F Graziano
    Medical Oncology Unit, Hospital of Urbino, Italy
    Ann Oncol 15:489-92. 2004
    ..In this perspective, we investigated E-cadherin gene (CDH1) promoter hypermethylation in gastric carcinomas and its correlation with E-cadherin protein expression...
  20. pmc Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
    BMC Cancer 11:247. 2011
    ..Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab...
  21. pmc A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population
    Soroush Nasri
    Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, Dunedin 9054, Aotearoa New Zealand
    BMC Cancer 8:138. 2008
    ..Recently, a new regulatory region essential for CDH1 transcription has been identified in CDH1 intron 2...
  22. ncbi request reprint Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
    Annamaria Ruzzo
    Institute of Biochemistry G Fornaini, University of Urbino, Urbino, Italy
    J Clin Oncol 25:1247-54. 2007
    ....
  23. ncbi request reprint Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
    Annamaria Ruzzo
    Institute of Biochemistry G Fornaini, University of Urbino, Urbino, Italy
    Clin Chem Lab Med 45:822-8. 2007
    ..We carried out a case-control study to evaluate whether polymorphisms of DNA repair and glutathione S-transferase (GST) genes modulate the risk of developing diffuse gastric cancer...
  24. ncbi request reprint Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
    Annamaria Ruzzo
    Medical Oncology Unit, Hospital of Urbino, Urbino, Italy
    J Clin Oncol 24:1883-91. 2006
    ..To investigate whether polymorphisms with putative influence on fluorouracil/cisplatin activity are associated with clinical outcomes of patients with advanced gastric cancer (AGC)...
  25. doi request reprint Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study
    David Rossi
    Oncology Unit, S Salvatore Hospital, Pesaro, Italy
    Clin Lung Cancer 9:280-4. 2008
    ..Otherwise, only a few studies are available in NSCLC. The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC...
  26. doi request reprint Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    J Cell Physiol 223:384-8. 2010
    ..Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions...
  27. doi request reprint VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population
    Paolo Maltese
    Department of Biomolecular Sciences, University of Urbino, Via Saffi, 2 61029, Urbino, Italy
    Int J Colorectal Dis 24:165-70. 2009
    ..We carried out a case-control study to evaluate whether polymorphisms of VEGF gene modulate the risk of developing colorectal cancer disease (CCD)...
  28. pmc High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
    Annamaria Ruzzo
    Department of Biomolecular Sciences, University of Urbino, Urbino, Italy
    Oncologist 17:823-9. 2012
    ..002). In patients with KRAS mutations, Let-7a analysis may serve to identify subgroups of patients who may still benefit from EGFR inhibition and this may open up new perspectives for alternative treatment strategies...
  29. ncbi request reprint Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients
    Annamaria Ruzzo
    Department of Biomolecular Sciences, University of Urbino, Urbino, Italy
    Curr Cancer Drug Targets 10:68-79. 2010
    ..Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatments conferred by KRAS and other gene mutations as well as the laboratory methods used to detect all these genetic variations...
  30. ncbi request reprint The G/A nucleotide change at cDNA position 2494 in the E-cadherin gene (CDH1): analysis in Italian patients
    Annamaria Ruzzo
    G Fornaini Institute of Biological Chemistry, University of Urbino, Urbino, Italy
    Tumour Biol 24:147-50. 2003
    ..4%. The novel CDH1 nucleotide change is uncommon in Italian patients with sporadic diffuse gastric cancer. Given these results, further analyses in large population-based studies are not advisable...
  31. doi request reprint A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases
    Vincenzo Catalano
    U O C Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio San Salvatore, Via Lombroso, 61122, Pesaro, Italy
    Gastric Cancer 16:411-9. 2013
    ..This study evaluates the efficacy and safety of a modified FOLFOX regimen in elderly patients with metastatic gastric cancer and presenting associated disease(s)...
  32. doi request reprint High safety profile and activity of oral vinorelbine in an elderly patient with metastatic breast cancer
    David Rossi
    Operative Oncology Unit, S Salvatore Hospital, Pesaro, Italy
    Breast Cancer 19:275-7. 2012
    ..The oral formulation of this drug had activity and a high safety profile, enabling the patient's wishes to be respected...
  33. doi request reprint Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study
    Vincenzo Catalano
    U O C Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio San Salvatore, Via Lombroso, 61122 Pesaro, Italy
    Gastric Cancer 15:419-26. 2012
    ..We aimed to evaluate the efficacy and toxicity of a sequential regimen with cisplatin, leucovorin, and 5-FU (PLF) followed by docetaxel in metastatic gastric cancer patients...
  34. doi request reprint HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer
    Vincenzo Catalano
    Medical Oncology, Azienda Ospedaliera Ospedale San Salvatore, Pesaro, Italy
    Histopathology 58:669-78. 2011
    ..HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer...
  35. doi request reprint A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome, Italy
    Oncology 82:75-82. 2012
    ..This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients...
  36. doi request reprint Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
    David Rossi
    Oncology Unit, S Salvatore Hospital, Pesaro, Italy
    Anticancer Drugs 19:733-7. 2008
    ..The combination of biweekly PLD and weekly paclitaxel was active in operable and locally advanced breast cancer with a manageable safety profile...
  37. doi request reprint Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV
    Bruno Vincenzi
    Medical Oncology, Università Campus Bio Medico, Via Alvaro del Portillo 200, 00128, Rome, Italy
    Support Care Cancer 21:1313-9. 2013
    ..Oxaliplatin-induced neuropathy is a dose-related side effect which occurs in almost 40 % of patients treated with oxaliplatin. Aim of the present study was to identify reliable clinical factors predicting its development and duration...
  38. ncbi request reprint Predictive factors for response to chemotherapy in colorectal cancer patients
    Bruno Vincenzi
    Medical Oncology, Campus Bio Medico University, Via Emilio Longoni, 69, 00155 Rome, Italy
    Crit Rev Oncol Hematol 52:45-60. 2004
    ..The results of this review provide the rationale basis for personalizing anticancer treatment in colorectal cancer patients by molecular and clinical features, aiming to improve response rate and reduce toxicities...
  39. ncbi request reprint Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
    Giammaria Fiorentini
    Department of Oncology Hematology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
    Anticancer Res 32:1387-95. 2012
    ....
  40. ncbi request reprint Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    David Rossi
    Oncology Hematology Department, S Salvatore Hospital, Pesaro, Italy
    Tumori 90:50-3. 2004
    ..The treatment consisted of weekly docetaxel, 40 mg/m2 in 1 hr for six weeks with two weeks of rest (1 cycle). A total of 87 administrations was delivered (median, 4; range, 1-12)...